lriog-2021-2

LRIOG N.2 2021

In this issue:

Original article

The vagina: clinical questions and unfulfilled therapeutic needs

Alessandra Grazziottin

PDF DOI:10.53146/lriog120216 Abstract

The vagina as an endocrine organ: clinical implications

Linda Vignozzi, Sarah Cipriani, Elisa Maseroli, Irene Scavello, Vincenza Di Stasi, Ilaria Cellai, Sandra Filippi, Paolo Comeglio

PDF DOI:10.53146/lriog120217 Abstract

The vagina, a sensual and erotic organ: anatomofunctional evidence

Emmanuele A. Jannini, Fiorenza Pesce

PDF DOI:10.53146/lriog120218 Abstract

The vagina and its microbiota (resident and dynamic)

Francesco De Seta, Gabriella Zito, Giuseppe Ricci, Simona Franz

PDF DOI:10.53146/lriog120219 Abstract

The vagina, oncological target: VaIN and therapeutic strategies

Francesco Sopracordevole, Nicolò Clemente, Anna del Fabro

PDF DOI:10.53146/lriog120220 Abstract

The pelvic floor: common elements of the physiotherapy and gynecological evaluation

Arianna Bortolami

PDF DOI:10.53146/lriog120221 Abstract

The vagina: emerging evidence on the anti-inflammatory role of testosterone

Linda Vignozzi, Elisa Maseroli, Ilaria Cellai, Sandra Filippi, Paolo Comeglio, Sarah Cipriani, Irene Scavello, Giulia Rastrelli, Margherita Frison, Mario Maggi

PDF DOI:10.53146/lriog120222 Abstract

The vagina: therapeutic role of prasterone

Linda Vignozzi, Irene Scavello, Elisa Maseroli, Vincenza di Stasi, Sarah Cipriani

PDF DOI:10.53146/lriog120223 Abstract

The vagina: therapeutic role of ospemifene

Novella Russo

PDF DOI:10.53146/lriog120224 Abstract

The vagina: therapeutic role of estrogens

Anna Maria Paoletti, Manuela Neri

PDF DOI:10.53146/lriog120225 Abstract

Gonorrhea a threatening infection in gynecology and obstetrics

Alessandra Graziottin, Elena Boero, Chiara Limongi

PDF DOI:10.53146/lriog120226 Abstract

Chronic vulvar pain, recurrent candidiasis and familial diabetic risk.
Critical factors emerged from the VuNet on 1183 women – Part II

Alessandra Graziottin, Dania Gambini, Elena Boero, Filippo Murina, ricercatori del Gruppo VuNet

PDF DOI:10.53146/lriog120227 Abstract

Quarterly magazine: Nr.2 – 2021

e – ISSN: 1824 – 0283

Scarica il pdf     download_pdf


Chronic vulvar pain, recurrent candidiasis and familial diabetic risk

Chronic vulvar pain, recurrent candidiasis and familial diabetic risk
Critical factors emerged from the VuNet on 1183 women – Part II

Alessandra Graziottin1,2 – Orcid, Dania Gambini2, Elena Boero2– Orcid, Filippo Murina3,4 – Orcid, ricercatori del gruppo Vu-net 

1 – Center of Gynecology and Medical Sexology, H. San Raffaele Resnati Milan

2 – Graziottin Foundation for the treatment of pain in women – Onlus

3 – Lower Genital Tract Pathology Service, V. Buzzi Hospital – University of Milan

4 – Italian Vulvodynia Onlus Association

Corresponding author: Alessandra Graziottin

direzione@studiograziottin.it


DOI: 10.53146/lriog1202127

Abstract

The VuNet (Vulvodynia Network) Project is an observational study set out to investigate the epidemiological characteristics and comorbidities of chronic vulvar pain. It involved 1183 women, enrolled between December 2016 and November 2018 in 21 Italian medical centers. Supported by the collected evidence that 32% patients with vulvar pain were affected by recurrent vulvo- vaginal candidiasis (RVVC), this article aims at analyzing the role of Candida infections in the genesis of vulvar pain and dyspareunia, and diabetes, or familiarity for diabetes, as a key predisposing factor. The recurrent/persistent inflammation associated with an aberrant immune-allergic reaction to Candida antigens may be a strong co-factor for developing vestibulodynia in this cluster of patients. The co-prevalence of 17.5% patients reporting food or respiratory allergies suggests a parallel predisposition to the development of allergic reactions. The anamnesis revealed a higher rate of diabetes in first- and second-degree relatives of the patients, both from the mother’s (8.4%) and father’s side (8.6%), versus the Italian national prevalence of 5.3% for the population un- der 65. Genetic predisposition for diabetes alters the carbohydrate metabolism predisposing to vulvovaginal candidiasis. Collectively, our data highlight the importance of investigating metabolic vulnerabilities to diabetes, both in the patient and her family, and encourage appropriate lifestyles, including: a net reduction in the consumptions of glucose or saccharose, body weight control, and daily aerobic exercise to reduce peripheral insulin resistance. The ultimate goals are reducing predisposing factors for candidiasis, vestibulodynia and coital pain in this cluster of patients, and tailoring treatment accordingly.

Keywords: vulvovaginal candidiasis; vulvar pain; vestibolodynia; dyspareunia; diabetes.


Available in LRIOG Nr.2 – 2021

e-ISSN: 1824-0283


Download the pdf  download_pdf


Gonorrhea, a threatening infection in gynecology and obstetrics

Gonorrhea, a threatening infection in gynecology and obstetrics

Alessandra Graziottin1,2 – Orcid , Elena Boero1– Orcid  , Chiara Limongi

1 –  Graziottin Foundation for the treatment of pain in women – Onlus

2 – Center of Gynecology and Medical Sexology, H. San Raffaele Resnati Milan

Corresponding author: Alessandra Graziottin

direzione@studiograziottin.it


DOI: 10.53146/lriog1202126

Abstract

Gonorrhea is the second most common sexually transmitted bacterial infection worldwide after chlamydia. Women present a different and unsuspected gender vulnerability, with diagnostic and therapeutic delays that can and must be avoided. Gonorrhea is caused by the vertically and sexually transmitted bacterium Neisseria gonorrhoeae, whose prevalence is aggressively increasing worldwide. Diagnostic and therapeutic timeliness in women is hampered by lack of specificity and short duration of cervico-vaginal symptoms, modesty of urethral symptoms (urethritis), and limited knowledge of both oral and anal infections. Another element of insidiousness is the underestimation of the risks that gonorrhea entails, in terms of infertility and obstetric complications, chronic pelvic pain and injuries in distant organs, including conjunctivitis and gonococcal arthritis. The danger of the diagnostic delay is also expressed in the persistent infectivity of the patient, who continues infecting his/her sexual partners, and the fetus, in case of pregnancy. Growing antibiotic resistance is another serious alarm. The aim of the work is: to identify the key points for timely and effective diagnosis and treatment of gonorrhea in gynecology and obstetrics, with a focus on vaginal, endometrial, tubal, and pelvic; amniotic, placental, and fetal; oral and systemic vulnerability. Diagnostic difficulties and the current lack of a vaccine will be analyzed. The ultimate goal is to enhance the diagnostic and therapeutic timeliness of the gynecologist, in order to avoid both persistent underlying infectivity and multiple long-term complications.

Keywords: gonorrhea; sexually transmitted infection; gender vulnerability; infertility; antibiotic resistance.


Available in LRIOG Nr.2 – 2021

e-ISSN: 1824-0283


Download the pdf  download_pdf


The vagina: therapeutic role of estrogens

The vagina: therapeutic role of estrogens

Anna Maria Paoletti– Orcid , Manuela Neri2

1 – Full Professor of Gynecology and Obstetrics, University of Cagliari

2- Medical Director at the Gynecological Oncology Division of the Oncology Hospital of Cagliari, Brotzu Hospital (AOB)

Corresponding author: Anna Maria Paoletti

annapaoletti@unica.it


DOI: 10.53146/lriog1202125

Abstract

Estrogen plays a key role in the physiology of the vagina. The multi-layering of the vaginal epithelium is regulated by estrogen, as well as the function of the cervical glands, connective trophism, vascularization and the local immune system itself. All conditions of hypoestrogenism, be they physiological such as menopause, the menopausal transition period, the puerperium and jatrogens as treatments for estrogen dependent diseases, but also the use of hormonal contraceptives containing only progestin or low doses of ethinylestradiol are risk factors for atrophy of vagina and urinary tract, which is also modulated by estrogen. In all conditions of hypoestrogenism, detectable by a correct medical history, the Gynecologist must ask specific questions about the specific symptoms both in the fertile age and after the menopause, focusing on the genitourinary syndrome. A careful examination must make a differential diagnosis with dermatological or autoimmune diseases, and evaluate the intensity of the problem with internationally validated scales. Once the diagnosis has been established and contraindications to the use of estrogen have been excluded, the first-line treatment is the use of vaginal estrogens, such as estriol, estradiol or promestriene and conjugated estrogens. The proposed treatment must be monitored at regular intervals to assess its effectiveness, safety and acceptability.

Keywords: genitourinary syndrom; ospemifene; dyspareunia; vulvar atrophy; vaginal atrophy; dysuria.


Available in LRIOG Nr.2 – 2021

e-ISSN: 1824-0283


Download the pdf   download_pdf


The vagina: therapeutic role of ospemifene

La vagina: ruolo terapeutico dell’ospemifene

Novella Russo – Orcid

Demetra Medical Center: Center for Menopause

novella_russo@virgilio.it


DOI: 10.53146/lriog1202124

Abstract

The Genitourinary Syndrome of Menopause (GSM) is a progressive chronic condition that can be very bothersome for women. This disease, mainly due to the endocrinological changes occurring with menopause, is characterized by symptoms such as vaginal dryness, dyspareunia, itching, burning and dysuria. The marketing of a relatively new drug, Ospemifene, for the treatment of this clinical condition has given a new therapeutic option and prospective for a better quality of life in women affected by VulvoVaginal Atrophia (VVA). Ospemifene is a Selective Estrogen Receptor Modulator (SERM) and can also be prescibed to women with a history of breast cancer. The oral route of administration has shown to give higher adherence to treatment being preferable for many women to the vaginal route with a high satisfaction rate. In this article the main characteristics of the effects of Ospemifene on GSM have been elucidated and some of the most interesting studies have been illustrated. Women’s wording has been reported and particular attention given to their personal and familiar histories. Objective vulvar examination is described and aspects to be analysed in deep are reported. Therapeutic suggestions of a multimodal approach to the disease are made, although on this matter further scientific studies showing solid data are needed.

Keywords: genitourinary syndrom; ospemifene; dyspareunia; vulvar atrophy; vaginal atrophy; dysuria.


Available in LRIOG Nr.2 – 2021

e-ISSN: 1824-0283


Download the pdf  download_pdf


The vagina: therapeutic role of prasterone

The vagina: therapeutic role of prasterone

Linda Vignozzi1,2 – Orcid, Irene Scavello1 – Orcid, Elisa Maseroli1 – Orcid, Vincenzo Di Stasi– Orcid, Sarah Cipriani1,2 – Orcid

1 – Department of Biomedical, Experimental and Clinical Sciences “Mario Serio”, University of Florence

2 – SODc Andrology, Female Endocrinology and Gender Incongruence, Careggi University Hospital, Florence

Corresponding author: Linda Vignozzi

linda.vignozzi@unifi.it


DOI: 10.53146/lriog1202123

Abstract

Genitourinary menopause syndrome (GSM) is a chronic, progressive condition, which results from the effects of estrogenic and androgenic deficiency typical of menopausal age. It involves the genitourinary district and occurs with an extremely wide range of signs and symptoms. Dyspareunia, both superficial and deep, is among the main and most distressing symptoms of the GSM. Over the decades, different therapeutic approaches have been developed, aimed at improving the symptomatology and thus the quality of life of women, such as local estrogenic therapy, which until now has been considered the gold standard of GSM treatment. A new Prasterone formulation has recently been approved, which is biochemically and biologically identical to that of the endogenous human DHEA, an inactive steroid precursor that can be converted into estrogen and androgen into vaginal cells. The rationale of the use of prasterone is the theory of intracrinology, which is the proven ability of vaginal cells to convert an inactive compound into an active form. This molecule, absorbed locally, determines only a minimum increase in circulating hormonal values, which remains be- low the threshold of physiologic levels for menopausal women.

Keywords: prasterone; genitourinary syndrome; menopause; atrophy.


Available in LRIOG Nr.2 – 2021

e-ISSN: 1824-0283


Download the pdf  download_pdf